MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...

in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his colleagues ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Nov 2024 - Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax ...